Syncing versus linking: A patient’s clinical trial journey
In a world where precision medicines are becoming more and more common, and the development of...
In a world where precision medicines are becoming more and more common, and the development of...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and analyzed a high-risk non–muscle invasive bladder cancer (HR-NMIBC) population using HealthVerity Marketplace. By using linked, privacy-compliant cla...